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Abstract Implantation of human embryonic stem cells
(hES), derived progenitors or mature cells derived from
hES has great therapeutic potential for many diseases. If
hES would come from genetically unrelated individuals, it
would be probably rejected by the immune system of the
recipient. Blood groups, MHC and minor antigens are the
immunogenetic hurdles that have to be crossed for
successful transplantation. Autologous transplantation with
adult stem cells would be the best approach but several
elements argue against this option. Classical immunosup-
pression, depleting antibody, induction of tolerance and
stem cell banking are alternative methods that could be
proposed to limit the risk of rejection.
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Abbreviations
hES Human embryonic stem cells
NK Natural killer
MHC Major histocompatibility complex class
HLA Human leukocyte antigen
mHC Minor histocompatibility antigen
GvHD Graft-versus-host disease
Introduction
Although human embryonic stem cells (hES) have been
studied for more than 50 years [1, 2], it is only recently that
they became a sensitive topic. hES cells are pluripotent
stem cells, isolated from the inner cell mass of human
blastocysts. The two salient characteristics of ES cells are
that they are undifferentiated and that they are capable of
self renewal.
HES cells are very convenient for clinical purposes
because they can be derived into different progenitor cells
types, being an inexhaustible source of mature cells for
organs and tissues.
Implantation of progenitor or mature cells derived from
hES has great therapeutic potential for many diseases and
can be viewed as the “holy grail” of transplantation and
regenerative medicine.
The origin of hES is of great importance since trans-
planting a patient with cells from a genetically unrelated
donor (allogenic transplantation) will trigger a detrimental
immune response. Seminal publications strongly suggest
that hES cells possess immune-privileged properties [3].
Thus, transplantation of hES into organs like the brain,
which is also considered an immune-privileged site, was
viewed as a typical example of a potentially curative
treatment of neurodegenerative diseases without incurring
the risk of an unwanted immune reaction [4]. More recent
works imply that the risk of rejection by the immune
system of allogenic hES or their progenitor cells warrants
serious thought. T lymphocytes and natural killer (NK)
cells are able to target hES and their progenitor cells, and
immunosuppressive treatments have to be included in
protocols of transplantation. Interestingly, recent publica-
tions strongly suggest that hES cells possess mechanisms
that protect them from the immune system. Indeed, hES
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cells seem to be able to escape the destruction mediated by
T or NK cells by means of a serine protease inhibitor [5].
In this review, we will discuss extensively the immune
status of hES cells and we will describe the immune hurdles
to the transplantation of hES cells and derived progenitors.
Finally, we will focus on several approaches to overcome
the barriers of genetically unrelated individual. As a matter
of fact, hES cells, their progenitors or fully mature cells
possess different properties. This could be a crucial factor
in determining the risks and the chances of success of hES
cells transplantation.
Immune barriers to hES transplantation
The problems arising from transplantation—whether of
tissue, organs or stem cells—between two genetically
unrelated individuals (allogenic) are similar. If the immune
response is not suppressed, the body will definitely reject
the graft, i.e. in this case the ES cells. Rejection occurs
because of the presence of multiple different antigens
between the donor and the recipient that activate the innate
and adaptive immune systems. Three “families” of trans-
plant antigens are known to play an important part in
inducing solid organ rejection:
– The human ABO blood-group antigens
– The major histocompatibility complex (MHC)
– The minor histocompatibility antigens.
The human ABO blood-group antigens
ABO antigens are the result of structural polymorphisms in
carbohydrate residues bound to the cell surface. Nearly all
cells, but particularly erythrocytes, express these ABO
antigens. Organ transplantation between an ABO incom-
patible donor and recipient cause hyperacute rejection,
mediated by preformed specific antibodies to ABO antigens
that activate the complement cascade [6]. ABO incompat-
ibility leads to hyperacute rejection in vascular organ
transplantation, but it does not cause problems in hemato-
poietic stem cell transplantation. This is due to the fact that
in hematopoietic stem cell transplantation, the recipient
blood group will be replaced by the donor blood group. The
immune system reconstituted after the transplantation will
be tolerant to recipient ABO antigens expressed by the non
hematopoietic cells of the recipient. As far as we know,
only one study investigated the expression of A and B
antigens in hES cells, demonstrating the expression of AB
antigens according to the ABO genotype embryonic stem
cells [7]. Several A genotype hES cell lines stained positive
with anti-B antibody. After derivation of hES into
hepatocyte- and cardiomyocyte-like cells at different stages
of maturation, originating from a B blood-group human
embryonic stem cells (hESC) line, showed that hepatocyte-
like cells expressed B antigens whereas cardiomyocyte-like
cells were negative [7]. In the human system, ABO
incompatibility between donor ES cells and the recipient
that would lead to hyperacute rejection, remains to be
proven, but a possible solution might be to use of ES cells
from a type O blood donor (universal donor).
The MHC
The human leukocyte antigen (HLA) gene is the most
highly polymorphic gene in the human genome. Two major
gene products are encoded by the HLA, the major
histocompatibility complex class I (MHC-I), and the major
histocompatibility complex class II (MHC-II). The classical
MHC-I molecules (HLA-A, HLA-B and HLA-C) are
expressed by nearly all nucleated cells, and the classical
MHC-II molecules (HLA-DR, HLA-DQ and HLA-DP) are
expressed constitutively by dendritic cells, macrophages or
B cells but can be induced by cytokines like interferon
gamma (IFN-γ) on nearly every cell type. The role of MHC
class I and II expressed by dendritic cells is to present
antigenic peptides to specific T cells in the lymph nodes.
Specific T cells will migrate to the tissue and target cells
that present the same antigen. If the antigen is from an
unrelated individual or emanates from a microorganism, T
cells will destroy it. MHC antigens are also strongly
immunogenic, and thus the presentation of MHC from an
MHC mismatched donor will activate the recipient's
immune system. Therefore, the expression of MHC at the
cell surface is the greatest immunological barrier to
transplantation. In hematopoietic stem cell transplantation,
incompatible MHC between donor and recipient is the
source of either graft-versus-host disease (GvHD)—where
graft T cells can react to recipient's HLA—or graft
rejection, where the receiver’s T cells attack the graft. The
highest risk of GvHD or graft rejection is between HLA-
mismatched individuals. In solid organ transplantation, the
immune reaction is only direct into the graft direction, the
immune system being on host origin only.
The question of MHC expression by ES cells is crucial and
has been scrutinized by several groups. Drukker et al. [8]
showed that ES cells express very low levels of MHC-I
protein on their surface, and after differentiation in vitro or in
vivo, the level of MHC-I expression increases only slightly.
However, when ES cells are treated with IFN-γ, a marked
induction of MHC-I can be observed. On the other hand,
MHC-II is not expressed on ES cells, even when they are
activated with IFN-γ. Another publication [9] reports that
human pre-implantation embryos do not express MHC-I or
MHC-II.
At least, two aspects would increase the immunogenicity
of ES cells. Even if ES cells originally express MHC-I in
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small amounts, this would naturally increase after their
normal differentiation into a different lineage, at least as far
as MHC-I is concerned. Moreover, IFN-γ is often present
during infection or inflammation and this would also
increase the level of MHC-I, but the risk of rejection by
allogenic ES cells has to be addressed.
In addition to the classical MHC protein, the role of non-
classical MHC protein like HLA-G and E that can bind the
receptors of NK cells KIR2DL4 and NKG2A, respectively,
of NK cells, remain to be addressed in the context of the
alloimmune response.
The minor histocompatibility antigens
Without a doubt, ES cells express minor histocompatibility
antigen (mHC). These antigens are mainly derived from
mitochondrial DNA (mDNA) and from Y-chromosome
genes (H-Y antigens). But all polymorphic proteins (different
between the recipient and the ES cells) are potentially
immunogenic and should be considered minor antigens. They
are presented as peptides by the donor's antigen-presenting
cells (APC). Y-chromosome gene products are responsible
for immunological reactions in transplants between males
and females, female T cells responding to H-Y antigens. The
immune reactivity of mHC is less strong than MHC
incompatibility but it can induce allograft rejection and
should not be underestimated [10].
Allorecognition pathway
The immunological mechanism that causes rejection and
involves recipient CD4+ T cells consists of two distinct
pathways; the direct (Fig. 1a) and the indirect (Fig. 1b)
allorecognition pathway. In the direct pathway, a graft is
transplanted with APC, or with APC- precursors that will
differentiate into APC after transplantation. These trans-
planted APC migrate to the nearest lymph node where
they meet recipient T cells. These recipient CD4+ T cells,
that express T cell receptors, bind to the MHC-II–peptide
complex expressed by the donor APC, which triggers an
immune reaction. The indirect pathway is also triggered
when the recipient’s APC express the MHC-II receptor
with donor antigens such as dying or apoptotic–necrotic
transplanted cells. The recipient's APC activates the
recipient's T cells in the same manner as in the case of
the direct pathway, through co-stimulatory molecules such
as CD40, CD80 or CD86. The immune reaction with
transplanted ES cells would probably involve mainly the
indirect pathway. ES cells have no APC properties but can
be derived into APC. However, APC could be derived
from ES cells, in such situation APC would originate from
the donor and could drive the direct pathway (Fig. 1b)
[11].
In addition to T cells, NK could also be part of the
alloreaction to hES cells. NK cells are a sub-population of
cells from the innate immune system and express different
activating and inhibitory receptors (Fig. 2). According to
the “missing-self” hypothesis [12], NK cell receptors bind
to self-MHC-I and inhibit NK cell activity, whereas NK cell
cytolytic activity is directed against cells that have lost self-
MHC-I expression. NK cell receptors need no specific
rearrangement like T cells do, they are fully functional and
their repertoire of receptors differs from individual to
individual. The absence of MHC class I in hES cells make
them potential targets for NK cells.
Immune response to allotransplanted ES cells
The amount of information available on the immune
properties of ES cells is not extensive. Before using these
cells in a clinical trial, their immunogenicity must be well
understood. Drukker et al. [13] answered part of this
question by using two different animal models with hES
cells. The first model, based on an immunocompetent
mouse, was used to clarify the mechanism underlying hES
cell rejection. The purpose of the second one, a mouse
which carried the human peripheral blood lymphocytes,
was to test the immune response to differentiated and
undifferentiated hES cells. In the first model, after 1 month
of experiments, the injected hES cells failed to develop into
teratomas, contrary to hES cells in NOD/SCID mice that
derived into teratomas. Drukker et al. demonstrated that the
rejection mechanism was mediated by T cells. By using
humanized mice, hES cells were not rejected and developed
normally into teratomas, in contrast to human adult skin
grafts, which were infiltrated by leukocytes. Some inves-
tigators suggest that if these ES cells escaped rejection, it
was probably due to their immunological immaturity,
characterized by the non-expression of MHC-II and co-
stimulatory molecules and the weak expression of MHC-I.
Moreover, they showed by means of a DNA microarray that
half of the immune genes expressed in the hematopoietic cell
line, were not up-regulated on human ES cells. This could
justify reducing immunosuppressive drugs in ES cell
transplantation. It has to be emphasized, however, that those
experiments were performed over a short period of time
whereas conducting them on a long-term basis might reveal
if the weak expression of MHC-I on ES cells would increase
after their derivation and maturation.
Several studies show that ES cells can escape immune
recognition. Human ES cells have been shown to survive
for many weeks after transplantation in rats [14]. It should
be noted that all these studies were carried out during
immunosuppressive treatment.
Other groups have described that murine ES cells
transplanted in allogenic recipients triggered the immune
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response and were rejected. Thus, Swijnenburg et al. [15]
demonstrated this very clearly in a non-invasive experiment
by injecting hES cells, transduced with a green fluorescent
protein, into the leg muscles of mice with either normal or
compromised immune systems. They screened the hES
cells by visualizing the fluorescence under a microscope
and showed that in the immunocompetent mice hES cells
died after a few days, whereas in the immunodeficient mice
ES cells survived longer. When transplantation was
repeated, hES cell death was accelerated, which highlighted
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the memory immune response mediated by CD4 T cells.
Finally, when normal mice were treated with immunosup-
pressive drugs (tacrolimus or sirolimus), hES cells survived
for a longer period.
The fact that MHC-I expresses so few ES cells could be
a real disadvantage when faced with NK cells. By assessing
the expression of MHC-I on ES cells Drukker et al. [8]
intended to find out if they would be recognized and lysed
by NK cells. Their standard cytotoxic assay revealed that
the level of ES cells killed was very low compared with that
of NK-sensitive cell lines. In the presence of IFN-γ, a slight
increase in the killing activity was observed. This could
mean that in the presence of ES cells, the killing
mechanism does not depend on MHC-I. Considering that
NK cells were not previously activated by pro-inflammatory
cytokines like IL-2 or IL-15, the response was less marked
than would be expected in the case of an inflammatory
condition.
Interestingly, it has been demonstrated that ES cells have
“a sort of” individual system of defense to avoid immune
rejection by T cells and especially by NK cells. ES cells
adopt 2 mechanisms to escape lysis by effector cells. The
first is composed of two ligands, CD95L and FasL, which
induce apoptosis of the cells expressing CD95 or Fas. This
may explain why there are so few T cells at the site where
ES cells are implanted. The second mechanism involved in
the survival of ES cells is the expression of high levels of
cathepsin B and a serine protease inhibitor (serpin), SPI-9
[16]. SPI-9 allows the destruction of granzym-B, a serine
protease released by cytotoxic T cells and NK cells.
Interestingly, when SPI-9 is knocked-down by siRNA, ES
cells are easily killed by target cells. Of note, several
malignant tumors express SPI-9, which allows them to
elude the immune system [17].
The expression of serpin seems absolutely crucial for ES
cells. Adult stem cells are the only source of cells that
regenerate after injury or normal homeostasis. If these adult
stem cells are infected by pathogens and therefore killed by
cytotoxic T cells or NK cells, the organism's survival is at
risk. A parallel can be drawn from a lethal dose of irradiation
that destroys the bone marrow and, as a consequence,
precludes the reconstitution of the hematopoietic cell
lineage.
Finally, serpin is most certainly responsible for the non-
rejection when the blastocyst encounters the mother's
uterine epithelium. In experiments involving mice models
[18], authors showed that after 4 to 5 days post-conception,
SPI-6 (mouse homologue of human SPI-9) was present in
the outer cell layers of the embryo, whereas elsewhere in
the embryo no SPI-6 was expressed. Later (12 days post-
conception) SPI-6 existed exclusively in the placenta.
Authors suggest that it was due to the expression of SPI-6
at the site of contact between embryo and mother that this
half-allogenic embryo (50% of the genes originated from
the father) was tolerated by the mother's immune system.
To overcome the immune barriers
At first glance, ES cells offer a great advantage compared
with other tissues. As they express HLA-I molecules in
very small amounts, their immunogenicity should be
accordingly low. However, due to the risk of teratoma and
also some uncertainty with regards to the in vivo
differentiation into specific lineages and tissue, it would
be more efficient to transplant progenitor or mature cells
rather than hES cells. The consequence would be an
increased risk of rejection [19]. This type of transplantation
could be viewed as a classical procedure in tissue or organ
transplantation with similar immunological risks of rejection.
In this part, we will discuss several ways to minimize the
allogenic reaction between donor and host, which is
achieved by means of classical immunosuppressive therapy
and the induction of tolerance in order to overcome the
immune barrier to stem cell transplantation.
Immunosuppressive therapy
To prevent rejection efficiently, the use of different
immunosuppressive drugs (ID), which possess diverse
mode of action, is recommended. While in the past acute
rejection of transplanted organs or tissue was common,
nowadays, thanks to these drugs, graft survival is steadily
on the increase.
The aim of ID is to impede four main cellular mechanisms
and to achieve the following effects; (a) blockade of T cell
proliferation (by anti-metabolites like azathioprine or myco-
phenolate mofetil); (b) reduction in inflammation (by
steroids); (c) inhibition of cytokine production (by calci-
neurin inhibitors like ciclosporine or tacrolimus); (d) finally,
depletion of macrophages/APC, T cells and/or B cells (by
monoclonal antibodies, like rabbit anti-thymocyte globulin
(rATG), rituximab or alemtuzumab).
Steroids or corticosteroids act as glucocorticoid receptor
agonists, which target transcription factors such as NF-κB.
This therapy is used to reduce inflammation and to induce
T cell apoptosis. Steroids are still very important immuno-
suppressors, especially in the first month after transplanta-
tion. Then, during the first year after transplantation,
steroids are reduced due to their side effects such as bone
loss or gastro-intestinal problems [20].
In 1968, azathioprine [21] was the first immunosuppres-
sive drug to be used on a regular basis in organ transplan-
tation. It acts by releasing a compound, 6-mercaptopurine,
which interacts with DNA synthesis. Azathioprine has
however been replaced progressively by mycophenolate
mofetil, which inhibits inosine-monophosphate deshydroge-
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nase (important for the synthesis of purine and selectively
used by T and B cells).
Cyclosporine (CsA) and tacrolimus (TaC) [22] are two
compounds that interact with calcineurin. Calcineurin is a
protein, which binds to a transcription factor, NFAT
(nuclear factor of activated T cells). This complex increases
the expression of IL-2 and stimulates the development and
the differentiation of T cells. Depending on the patient and
the side effects, either CsA or TaC is used but never both
together. These two ID have been proving their efficacy for
several years [20]. Sirolimus, or its derivative everolimus,
blocks the intracellular protein mammalian target of
rapamycin (mTOR), which activates T cells by signaling
the IL-2 receptor. By binding to mTOR, sirolimus blocks
the IL-2 pathway and inhibits T cell proliferation.
The role of immunossuppressive drugs is to block the
immune system but unexpected events have to be prevented
before using ID. NPC from a fetal origin or from hESC
have the potential to differentiate into mature neurons after
transplantation into the brain, opening the possibility of
regenerative cell therapy for neurodegenerative disorders
like Parkinson’s disease. To prevent the T and NK cells
immune response several ID have been used in vitro to test
their effect on culture NPC. We have demonstrated that
cyclosporine and dexamethasone strongly inhibit the
terminal differentiation of NPC into mature neurons [23].
Interestingly, this effect could be species dependent or
dependant of the source of stem cells. Indeed, in a mouse
model of NPC transplantation derived from mice neural
stem transplantation (and not from embryonic stem cell),
administration of cyclosporine A to adult animals increased
the numbers of NPCs within the neurogenic niche lining the
lateral ventricles. These findings suggest that cyclosporine
A has direct effects on NPCs both in vitro and in vivo,
making it a promising candidate molecule for developing
clinically relevant strategies to stimulate NPCs for brain
repair [24].
Therefore ID should be carefully considered in the
context of allogeneic transplantation of human hES if steps
of differentiation are request after transplantation.
The good regimen should combine the ability to inhibit
the T and the NK cells response without interfering with the
terminal differentiation into mature cells.
Depleting drugs and antibodies
Allograft rejection is a process involving mainly T cells,
and the specific depletion of recipient's T lymphocytes has
been actively developed using mostly mono- and poly-
clonal antibodies. Recombinant polyclonal rATG is at
present one of the most common drugs used to deplete T
cells. These polyclonal antibodies are obtained by immuniz-
ing rabbits with human lymphoid cells. rATG rapidly
induces lymphocytopenia by different processes such as
opsonization, apoptosis or complement-dependent lysis.
rATG does not only contain T cell antigens such as CD3,
CD4 and CD8, but also B cells antigens such as CD5, CD19
and CD20. In different studies on animal models it was
shown that rATG increases regulatory T cell subsets (T-regs)
and NK cells. T-regs play an important role in the regulation
of the activating T cells and prevent autoimmune disease and
GvHD [20].
A monoclonal antibody targeting anti-CD52 (alemtuzu-
mab) expressed by T cells, NK cells and monocytes is also
very efficient in depleting immune cells involved in the
rejection mechanism [25]. Last but not least, the binding of
the alpha chain of CD 25 by a chimeric monoclonal
antibody (basiliximab) blocks the IL-2 transduction path-
way and contributes to the prevention of rejection. As far as
we know, depleting antibody has never tested in model of
ES transplantation [26].
Induction of immune tolerance
Immune tolerance prevails when the immune system does
not react to antigens. Technically speaking, three types of
tolerance exist: (a) central tolerance or thymic tolerance
which occurs during lymphocyte maturation and takes
place in the thymus in the case of T cells and in the bone
marrow for B cells. Autoreactive T and B cells are
eliminated during these processes. (b) Peripheral tolerance,
or non-thymic tolerance, where mature lymphocytes move
into the periphery and do not react to foreign antigens. (c)
Acquired tolerance, an active process during which regula-
tory T cells block the activated T cells [11].
The induction of immune tolerance is the “holy grail” of
transplants specialists that consist in the blockade of the
alloimmune response to the graft without inhibiting the
immune response to microorganisms. Due to their weak
immunogenicity the use of ES cells has also been propose
to induce tolerance.
In 2002, Fändrich et al. [27] disclosed the first data on
tolerance induction using donor-derived embryonic stem
cells in a rat model. Instead of irradiating the host to defuse
the immune system, they injected rat embryonic stem cells
(rESC) isolated from blastocysts. Subsequently, these cells
were found in the liver, spleen, mesenteric lymph node
and thymus, which highlight the migration ability of these
cells. Moreover, these rESC develop into B cells and
monocytes, but no T or NK cells were found. rESC
tolerated a cardiac graft from the same rat strain as their
own. So probably, undifferentiated ES cells would not be
recognized by T cells and treatment based on ES cells is
possible, if the thymus is fully functional. But the risk of
teratomas is too high in humans if undifferentiated ES
cells are transplanted.
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Immunomodulatory properties of ES have to be consid-
ered in the context of transplantation but currently it is
mainly the mesenchymal cell population that has the
greatest potential of regulation with regards to T and NK
alloimmune response [28]. Dazzi reviews this topic in
another article of this issue.
Finally, the role of regulatory T cells coming from the
recipient or derived from embryonic stem cells of donor
origin to induce tolerance need to explored in the context of
embryonic stem cells transplantation.
Mixed chimerism
Mixed chimerism is a state where donor's and recipient's
hematopoietic cells co-exist in the same organism [29].
This situation has been observed after hematopoietic cell
transplantation. T cells originate from hematopoietic pro-
genitors. They respond to antigens in secondary lymphoid
tissues such as lymph nodes or the spleen. But in order to
respond to antigens, T cells need to learn to differentiate
between self and non-self antigens. This recognition
process takes place in the thymus. The thymus is divided
into several distinct functional areas, the cortex, the cortico-
medullary junction and the medulla. Progenitor T cells from
the bone marrow migrate to the thymus through blood
vessels at the cortico-medullary junction. Once in the
thymus, they proliferate, differentiate and migrate to the
cortex. In the cortex, the double negative CD4/CD8
thymocytes mature into double positive CD4/CD8 thymo-
cytes and encounter cortical thymic epithelial cells, which
express a peptide-MHC complex. The survival cells are
those, which express functional T cell receptors that in turn
bind to the peptide-MHC complex. After this first selection,
a second selection takes place, where the double positive
cells mature into single positive ones and return to the
medulla, where they leave the thymus to join the periphery
[30]. Knowing how the thymus works, one could imagine
that allogenic reactivity might be avoided by mixing donor
and recipient T cell progenitors. Chimeric recipients would
have specific immunological tolerance to the antigen
expressed by the donor, and they would not reject the
allograft. This promising technique would make it possible
to circumvent the immunological barrier that constitutes
HLA [11]. Promising results have already been obtained in
human kidney transplantation [31].
Autologous transplantation
To overcome the immune reaction and to achieve a perfect
immunological match between an embryonic stem or
progenitor cells of donor origin and the recipient, the use
of induced pluripotent stem cells (iPS) cells would be a
solution. iPS are obtain, by transducing four important
genes, Oct-4, c-Myc, Sox-2 and Klf-4, involved in the
development of ES cells, into a somatic cell. The resulting
iPS expresses the different characteristics of an ES cell [32–
35]. Recent work suggests that Oct-4 alone would be
sufficient to induced pluripotency in adult neural stem cells
[36].
However, new difficulties would arise. For example, in
disease with a well-documented genetic defect, the mutated
genes will be present in the iPS cells. This occurred in
patients with spinal muscular atrophy [37], and iPS
generated from fibroblasts of a sick child proliferated in
culture while maintaining the genotype of the disease. One
advantage of this phenomenon is that these iPS could be
used as a tool to study in depth the genetic defect and
develop new treatments, which would be much more
relevant than animal models. On the other hand, it would
be a pity if iPS cells produced a protein that is absent in the
deficient host. The immune system of the host may identify
this protein as being non-self and induce an immune reaction,
which is not wanted. In addition, it has to be pointed out that
several diseases, of which neurodegenerative diseases, have
unknown causes. What would happen if iPS from these
patients carried the defect? This will have to be clarified. As
far as the derivation of iPS is concerned, it would probably be
preferable in this context if the cells used for derivation
originated from a genetically unrelated donor [4].
Finally, preparation of cells of iPS of clinical grade,
suitable for transplantation into patients could be difficult to
achieve for time- and cost-effective reasons. The derivation,
maintenance and differentiation of iPS (like for hES) should
be accomplished under xeno-free culture conditions using
good manufacturing practice systems [38–41]. Guided-
differentiation methods will have to be established, leading
to homogeneous and reproducible cell populations that do
not form teratomas or cause cancer [42].
Stem cell banking
To overcome the problem described above, inherent in the
use of iPS for autologous transplantation, the characteriza-
tion of hES or iPS cell lines has to be explored.
Homozygous cell lines with frequent HLA haplotypes
could theoretically minimize the risk of reaction. Several
publications emanating from various countries specify the
minimal number of cell lines that would cover a significant
population with regards to their HLA typing [43–46].
However, these studies did not include high-resolution
HLA typing, and thus the significance of their results in
terms of rejection is limited. Coming from genetically
unrelated donors, the presence of minor antigens would
signify that even in the case of HLA compatibility as
determined by high-resolution typing, the risk of rejection
remains unless the patient's immune response is suppressed.
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Thus, the last hurdle to overcome is to determine the
level of immunosuppression required in each individual
case depending on compatibility. However, work of the past
decades in solid transplantation clearly indicates that it is
almost impossible to know beforehand the correct dosage
of immunosuppressive drugs that is required for a given
patient.
Conclusions and perpectives
ES cells are isolated from the inner mass cells of
blastocysts. After culture in specific media, these ES cells
can be derived into various types of cells or tissues.
Moreover, ES cells can renew themselves. One of the
biggest controversies surrounding ES cells is the use of
blastocysts, which are the result of an ovocyte fertilized by
a spermatozoid. Once the ES cells are isolated from the
inner mass cells and cultured, the residual blastocysts are
destroyed, which gives rise to ethical issues. Consequently,
other solutions need to be found that afford sufficient
amounts of ES cells without the use of blastocysts.
Nowadays, several techniques exist, the most recent of
which consists of reprogramming somatic cells that
generate iPS cells, which have the same properties as ES
cells.
Several groups show that if ES cells are cultured in well-
defined conditions, they are able to derive into other cells
tissues such as neurons [47], cardiomyocytes [48] and
hepatocytes [49], to name but a few, each of which possess
the same specific properties as the original cells.
The fact that ES cells are able to renew themselves and
are derived into other types of cells renders them very
attractive for the replacement of injured or even destroyed
tissues. In transplantation, cytotoxic T lymphocytes CTL
and NK cells are the two main actors in the rejection
process. However, since receivers need to be treated with
ID in order to reduce the activities of T cells, only NK cells
can be taken into consideration.
As ES cells express very low amounts of MHC-I or none
at all, nor any MHC-II, they would be perfect targets for
NK cells, which lyse MHC-I negative cells, according to
the “missing-self” hypothesis. But it seems that this is not
the case [8] when unstimulated NK cells are used.
An important issue, common to many publications, is the
time factor. All the studies investigating the immunogenic
response of ES cells to NK or T cells were performed over a
short period of time. What would happen over time when
ES cells were cultured and derived? Frenzel et al. [50]
answered this question to some extent. In a mouse model
they assessed the difference between undifferentiated ES
cells and ES cells derived from cardiomyocytes (ESCM).
Although both cell types express similar low levels of
MHC-I, ESCM are neither recognized nor lysed by NK
cells, but ES cells are both recognized and lysed by NK
cells. The study showed that the difference lies in the
expression of NKG2D ligands, which are markedly
expressed by ES cells, whereas ESCM do not express
these ligands. This demonstrates that after derivation ES
cells may change their phenotype.
In order to prevent rejection of the ES cells, several
methods for monitoring the immune response are available.
Obviously, it is easier to culture ES cells in vitro than to
monitor them in vivo. The culture of ES cells and their
differentiation into progenitor cells make it possible to
conduct several analyses, such as crossmatch or mixed-
lymphocyte reaction, to test their immunogenicity. Cross-
match assays reveal the presence of antibodies in the serum.
The recipient's serum is incubated with ES cells, and by
means of FACS technology the binding of antibodies to
ABO, HLA or other antigens can be analyzed. A positive
result indicates a high risk of rejection. NK or T cells can be
analyzed as well by chromium release cytotoxic assay. ES
cells are incubated with radioactive chromium and the
functionality of the effectors cells is then estimated. The
amount of radioactive chromium released by ES cells in the
supernatant is indicative of NK or T cell activation.
The aim of this review is to highlight the immunoge-
nicity of ES cells. Despite the fact that ES cells are
undifferentiated cells with low or no expression of MHC-I
and MHC-II, their implantation triggers an immune
reaction. There were probably great expectations when
ES cells were only thought of as immuno-privileged cells.
But from more in in-depth investigations it appears that
ES cell transplantation could at some point be identical to
solid organ transplantation.
Several open questions were answered when Utermöhlen's
group [5] described for the first time the role of a serine
protease inhibitor expressed by ES cells, but also by some
tumor cells. One of the answers being the fact that
blastocysts are not rejected by the mother's immune system
or why so few T cells infiltrate the site where ES cells are
implanted. As already mentioned, serpin is important to the
survival of ES cells. But what would happen if these ES cells
were infected with pathogens? A serious problem would
arise if NK cells or CTL started to kill infected adult stem
cells. Guidotti et al. [51, 52] shed light on a very interesting
property of CTLs, in that in a mouse model infected with
hepatitis B virus (HBV) hepatocytes were not killed by
CTLs; instead, without killing the infected cells, CTLs
inhibited expression and replication of the HBV by secreting
IFN-γ and TNF-α. But this process has still to be
reproduced using infected ES cells.
Finally, the major point is to know the stage of
development of the ES cells that are intended for transplan-
tation. In the case of simple ES cells, the danger would lie in
the derivation of unwanted cells. ES cells would probably
532 Semin Immunopathol (2011) 33:525–534
not launch an immune reaction, thanks to serpins, and the
ES cells would survive. But in the case of progenitor cells, an
immune reaction would be triggered due to the expression
of ligands.
Obviously, it is necessary to conduct more investiga-
tions, but the concept that ES cells possess immune-
privileged properties and are the ideal source of cells for
transplantation has to be abandoned.
In fact, after so many years of evolution, there is no
exception, the immune system is not blind and ES cells
should be considered in the same light as tissue and organ
from a genetically unrelated donor.
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